Colistin treatment in older adults: why should we know more?

References

• Löffler C, Drewelow E, Paschka SD, et al. Optimizing polypharmacy among elderly hospital patients with chronic diseases–study protocol of the cluster randomized controlled POLITE-RCT trial. Implement Sci. 2014;9:151.
   PubMed Web of Science ®Google Scholar
• Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–307. doi: 10.1053/j.ackd.2010.05.002.
   PubMed Web of Science ®Google Scholar
• Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv. 2008;71(1):62–72. doi: 10.1002/ccd.21207.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341. doi: 10.1086/429323.
   PubMed Web of Science ®Google Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801–810. doi: 10.1007/s00228-015-1865-4.
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Bidell MR, Gandhi RG, et al. Colistin nephrotoxicity: meta-Analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8:ofab026.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884. doi: 10.1093/cid/cir611.
   PubMed Web of Science ®Google Scholar
• Deryke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54(10):4503–4505. doi: 10.1128/AAC.01707-09.
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–1728. doi: 10.1086/599225.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43(4):349–352. doi: 10.1016/j.ijantimicag.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. doi: 10.1186/cc3995.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee K-H, Yoo S, et al. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34(5):434–438. doi: 10.1016/j.ijantimicag.2009.06.028.
   PubMed Web of Science ®Google Scholar
• Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011;62(2):187–190. doi: 10.1016/j.jinf.2010.11.013.
   PubMed Web of Science ®Google Scholar
• Rocco M, Montini L, Alessandri E, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013;17(4):R174. doi: 10.1186/cc12853.
   PubMed Web of Science ®Google Scholar
• Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant pseudomonas aeruginosa. Clin Infect Dis. 2003;37(11):e154–e160. doi: 10.1086/379611.
   PubMed Web of Science ®Google Scholar
• John E, Bennett RD, Blaser MJ. Polymyxins (polymyxin B and colistin). In Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Vol. 8. Philadelphia: Elsevier; 2015. pp. 549–555.
   Google Scholar
• Drug & Diseases. eGFR using CKD-EPI. 2021. https://reference.medscape.com/calculator/251/egfr-using-ckd-epi-2021-update
   Google Scholar
• Avila M-P, Pacheco T, Arias S, et al. Is there a role for the therapeutic drug monitoring of colistin? An overview. Pharmaceuticals. 2020;13(3):42. doi: 10.3390/ph13030042.
   Web of Science ®Google Scholar
• Murugan R, Karajala-Subramanyam V, Lee M, et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010;77(6):527–535. doi: 10.1038/ki.2009.502.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–2449. doi: 10.1128/AAC.02634-15.
   PubMed Web of Science ®Google Scholar
• Langenberg C, Bagshaw SM, May CN, et al. The histopathology of septic acute kidney injury: a systematic review. Crit Care. 2008;12(2):R38. doi: 10.1186/cc6823.
   PubMed Web of Science ®Google Scholar
• Alobaidi R, Basu RK, Goldstein SL, et al. Sepsis-associated acute kidney injury. Semin Nephrol. 2015;35(1):2–11. doi: 10.1016/j.semnephrol.2015.01.002.
   PubMed Web of Science ®Google Scholar
• Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol. 2015;35(1):64–74. doi: 10.1016/j.semnephrol.2015.01.007.
   PubMed Web of Science ®Google Scholar
• Emlet DR, Shaw AD, Kellum JA. Sepsis-associated AKI: epithelial cell dysfunction. Semin Nephrol. 2015;35(1):85–95. doi: 10.1016/j.semnephrol.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med. 1995;332(19):1280–1284. doi: 10.1056/NEJM199505113321907.
   PubMed Web of Science ®Google Scholar
• Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014;20(6):588–595. doi: 10.1097/MCC.0000000000000153.
   PubMed Web of Science ®Google Scholar
• Chelazzi C, Villa G, Mancinelli P, et al. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19(1):26. doi: 10.1186/s13054-015-0741-z.
   PubMedGoogle Scholar
• Ince C. The Central role of renal microcirculatory dysfunction in the pathogenesis of acute kidney injury. Nephron Clin Pract. 2014;127(1-4):124–128. doi: 10.1159/000363203.
   PubMedGoogle Scholar
• Jung S-Y, Kwon J, Park S, et al. Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy. PLOS One. 2018;13(2):e0191290. doi: 10.1371/journal.pone.0191290.
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–1378. doi: 10.1038/ki.2011.47.
   PubMed Web of Science ®Google Scholar
• Christov M, Waikar SS, Pereira RC, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 2013;84(4):776–785. doi: 10.1038/ki.2013.150.
   PubMed Web of Science ®Google Scholar
• Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis. 2013;20(5):390–395. doi: 10.1053/j.ackd.2013.05.004.
   PubMed Web of Science ®Google Scholar
• Neugarten J, Silbiger SR. Effects of sex hormones on mesangial cells. Am J Kidney Dis. 1995;26(1):147–151. doi: 10.1016/0272-6386(95)90168-X.
   PubMed Web of Science ®Google Scholar
• Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100(3):352–357. doi: 10.7326/0003-4819-100-3-352.
   PubMed Web of Science ®Google Scholar
• Neugarten J, Sandilya S, Singh B, et al. Sex and the risk of AKI following cardio-thoracic surgery: a meta-analysis. CJASN. 2016;11(12):2113–2122. doi: 10.2215/CJN.03340316.
   PubMed Web of Science ®Google Scholar
• McMahon GM, Zeng X, Waikar SS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. 2013;173(19):1821–1828. doi: 10.1001/jamainternmed.2013.9774.
   PubMed Web of Science ®Google Scholar
• KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012. Report No.: VOLUME 2.
   Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients. Pharmaceutics. 2021;14(1):31. doi: 10.3390/pharmaceutics14010031.
   PubMed Web of Science ®Google Scholar
• Katip W, Rayanakorn A, Oberdorfer P, et al. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: a propensity score matching study. J Infect Public Health. 2023;16(8):1249–1255. doi: 10.1016/j.jiph.2023.05.024.
   PubMed Web of Science ®Google Scholar